The New Board has a wealth of credentials and networking to take this through to higher highs.
Note in particular our new chairman and his venture capital connections. Expect some great buying on-market for those that could not get any placement stock.
Also take note of prior directorships with Cochlear and Resmed. (COH = $8 Billion MC, RMD = $11 Billion MC)
In my opinion, with such board backing, Epat is primed to soar.
